20
views
0
recommends
+1 Recommend
1 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Associations between maternal characteristics and pharmaceutical treatment of gestational diabetes: an analysis of the UK Born in Bradford (BiB) cohort study

      research-article

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Objectives

          To identify the maternal characteristics associated with pharmaceutical treatment of gestational diabetes mellitus (GDM).

          Design

          Prospective birth cohort study.

          Setting

          Bradford, UK.

          Participants

          762 women from the Born in Bradford (BiB) cohort who were treated for GDM in a singleton pregnancy. BiB cohort participants were recruited from 2007 to 2010. All women booked for delivery were screened for GDM between 26 and 28 weeks of gestation using a 75 g 2-hour oral glucose tolerance test (OGTT).

          Outcome measure

          GDM treatment type: lifestyle changes advice (lifestyle changes), lifestyle changes advice with supplementary insulin (insulin) and lifestyle changes advice with supplementary metformin (metformin).

          Results

          244 (32%) women were prescribed lifestyle changes advice alone while 518 (68%) were offered supplemental pharmaceutical treatment. The odds of receiving pharmaceutical treatment relative to lifestyle changes advice alone were increased for mothers who were obese (OR 4.6, 95% CI 2.8 to 7.5), those who smoked (OR 2.6, 95% CI 1.2 to 5.5) and had higher fasting glucose levels at OGTT (OR 2.1, 95% CI 1.6 to 2.7). The odds of being prescribed pharmaceutical treatment rather than lifestyle changes advice were lower for Pakistani women (OR 0.7, 95% CI 0.4 to 1.0)) than White British women. Relative to insulin treatment, metformin was more likely to be offered to obese women than normal weight women (relative risk ratio, RRR 3.2, 95% CI 1.3 to 7.8) and less likely to be prescribed to women with higher fasting glucose concentrations at OGTT (RRR 0.3, 95% CI 0.2 to 0.6).

          Conclusions

          In the BiB cohort, GDM pharmaceutical treatment tended to be prescribed to women who were obese, White British, who smoked and had more severe hyperglycaemia. The characteristics of metformin-treated mothers differed from those of insulin-treated mothers as they were more likely to be obese but had lower glucose concentrations at diagnosis.

          Related collections

          Most cited references56

          • Record: found
          • Abstract: not found
          • Book: not found

          A simple sequentially rejective multiple test procedure

            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Metformin versus insulin for the treatment of gestational diabetes.

            Metformin is a logical treatment for women with gestational diabetes mellitus, but randomized trials to assess the efficacy and safety of its use for this condition are lacking. We randomly assigned 751 women with gestational diabetes mellitus at 20 to 33 weeks of gestation to open treatment with metformin (with supplemental insulin if required) or insulin. The primary outcome was a composite of neonatal hypoglycemia, respiratory distress, need for phototherapy, birth trauma, 5-minute Apgar score less than 7, or prematurity. The trial was designed to rule out a 33% increase (from 30% to 40%) in this composite outcome in infants of women treated with metformin as compared with those treated with insulin. Secondary outcomes included neonatal anthropometric measurements, maternal glycemic control, maternal hypertensive complications, postpartum glucose tolerance, and acceptability of treatment. Of the 363 women assigned to metformin, 92.6% continued to receive metformin until delivery and 46.3% received supplemental insulin. The rate of the primary composite outcome was 32.0% in the group assigned to metformin and 32.2% in the insulin group (relative risk, 0.99 [corrected]; 95% confidence interval, 0.80 [corrected] to 1.23 [corrected]). More women in the metformin group than in the insulin group stated that they would choose to receive their assigned treatment again (76.6% vs. 27.2%, P<0.001). The rates of other secondary outcomes did not differ significantly between the groups. There were no serious adverse events associated with the use of metformin. In women with gestational diabetes mellitus, metformin (alone or with supplemental insulin) is not associated with increased perinatal complications as compared with insulin. The women preferred metformin to insulin treatment. (Australian New Zealand Clinical Trials Registry number, 12605000311651.). Copyright 2008 Massachusetts Medical Society.
              Bookmark
              • Record: found
              • Abstract: not found
              • Article: not found

              Diagnosis and classification of diabetes mellitus.

              (2008)
                Bookmark

                Author and article information

                Journal
                BMJ Open
                BMJ Open
                bmjopen
                bmjopen
                BMJ Open
                BMJ Publishing Group (BMA House, Tavistock Square, London, WC1H 9JR )
                2044-6055
                2021
                3 November 2021
                : 11
                : 11
                : e053753
                Affiliations
                [1 ]departmentSchool of Sport, Exercise and Health Sciences , Loughborough University , Loughborough, UK
                [2 ]departmentSchool of Science , Loughborough University , Loughborough, UK
                [3 ]departmentInstitute of Sport, Exercise and Health, Division Surgery Interventional Science , University College London , London, UK
                Author notes
                [Correspondence to ] Dr William Johnson; w.o.johnson@ 123456lboro.ac.uk
                Author information
                http://orcid.org/0000-0002-4592-3680
                Article
                bmjopen-2021-053753
                10.1136/bmjopen-2021-053753
                8572403
                34732497
                a3686b0d-2464-4465-9d29-9caf3374ac40
                © Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY. Published by BMJ.

                This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits others to copy, redistribute, remix, transform and build upon this work for any purpose, provided the original work is properly cited, a link to the licence is given, and indication of whether changes were made. See:  https://creativecommons.org/licenses/by/4.0/.

                History
                : 24 May 2021
                : 14 September 2021
                Funding
                Funded by: FundRef http://dx.doi.org/10.13039/501100000857, Loughborough University;
                Award ID: N/A
                Funded by: NIHR Collaboration for Applied Health Research and Care (CLAHRC);
                Award ID: IS-CLA-0113-10020
                Funded by: FundRef http://dx.doi.org/10.13039/100010269, Wellcome;
                Award ID: WT101597MA
                Funded by: NIHR Leicester Biomedical Research Centre;
                Award ID: N/A
                Funded by: UK Medical Research Council (MRC);
                Award ID: MR/P023347/1
                Funded by: NIHR Clinical Research Network;
                Award ID: N/A
                Categories
                Epidemiology
                1506
                1692
                Original research
                Custom metadata
                unlocked

                Medicine
                diabetes in pregnancy,epidemiology,public health
                Medicine
                diabetes in pregnancy, epidemiology, public health

                Comments

                Comment on this article